Table 3 Association of MMP12 polymorphisms with clinical stage and ER/PR status in breast cancer patients
MMP12 genotype | Â | Â | Â | Â |
|---|---|---|---|---|
| Â | TNM stage No. (%) | Â | Â | |
Analyzed according to stage of cancer | 0, I, or II | III or IV | Â | P |
A-82G | Â | Â | Â | Â |
   AA | 876 (95.1) | 113 (93.4) |  | 0.42 |
   AG/GG | 45 (4.9) | 8 (6.6) |  |  |
A1082G (Asn357Ser) | Â | Â | Â | Â |
   AA | 606 (80.5) | 81 (79.4) |  | 0.80 |
   AG/GG | 147 (19.5) | 21 (20.6) |  |  |
Presence of any minor genotypesa | Â | Â | Â | |
   No | 563 (75.6) | 74 (74.0) |  | 0.73 |
   Yes | 182 (24.4) | 26 (26.0) |  |  |
Analyzed according to ER/PR status | ER+/PR+ No. (%) | ER-/PR- No. (%) | ER+/PR- or ER-/PR+ No. (%) | Â |
A-82G | Â | Â | Â | Â |
   AA | 401 (97.1) | 188 (93.5) | 144 (95.4) | 0.11 |
   AG/GG | 12 (2.9) | 13 (6.5) | 7 (4.6) |  |
A1082G (Asn357Ser) | Â | Â | Â | Â |
   AA | 251 (77.0) | 145 (84.8) | 102 (83.6) | 0.07 |
   AG/GG | 75 (23.0) | 26 (15.2) | 20 (16.4) |  |
Presence of any minor genotypesa | Â | Â | Â | |
   No | 238 (74.1) | 133 (78.2) | 96 (79.3) | 0.41 |
   Yes | 83 (25.9) | 37 (21.8) | 25 (20.7) |  |